When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
MKGAY - Pfizer and Merck KGaA's Bavencio extends survival in urothelial cancer study
Merck KGaA ADR
Results from a Phase 3 clinical trial, JAVELIN Bladder 100, evaluating Pfizer (NYSE:PFE) and alliance partner Merck KGaA's (OTCPK:MKGAY) Bavencio (avelumab) for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial cancer (UC) whose disease did not progress in induction chemo met the primary endpoint of overall survival (OS).
More news on: Pfizer Inc., Merck KGaA ADR, Healthcare stocks news,